- Conditions
- Dravet Syndrome
- Interventions
- ETX101
- Drug
- Lead sponsor
- Encoded Therapeutics
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 11
- States / cities
- San Francisco, California • Aurora, Colorado • Miami, Florida + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Developmental and Epileptic Encephalopathy 1
- Interventions
- 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo
- Drug
- Lead sponsor
- Praxis Precision Medicines
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- La Jolla, California • Gulf Breeze, Florida • Chevy Chase, Maryland + 3 more
- Conditions
- Dravet Syndrome
- Interventions
- No Intervention
- Other
- Lead sponsor
- Encoded Therapeutics
- Industry
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
- Conditions
- SLC6A1 Neurodevelopmental Disorder (NDD), Developmental and Epileptic Encephalopathies (DEE)
- Interventions
- Not listed
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- MEF2C, DEE
- Interventions
- Observation
- Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- Not listed
- Enrollment
- 22,068 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- SCN8A Developmental and Epileptic Encephalopathy Syndrome
- Interventions
- NBI-921352, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more
- Conditions
- Epileptic Encephalopathy, SCN2A Encephalopathy
- Interventions
- 1mg elsunersen, 0.5mg elsunersen
- Drug
- Lead sponsor
- Praxis Precision Medicines
- Industry
- Eligibility
- 1 Day to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more
- Conditions
- Developmental and Epileptic Encephalopathy
- Interventions
- LP352
- Drug
- Lead sponsor
- Longboard Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 66 Years
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 17 more
- Conditions
- SLC6A1
- Interventions
- Glycerol Phenylbutyrate
- Drug
- Lead sponsor
- Scripps Translational Science Institute
- Other
- Eligibility
- 2 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Developmental and Epileptic Encephalopathy (DEE)
- Interventions
- CBD-OS, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Orange, California + 14 more
- Conditions
- SCN2A-DEE, Epilepsy
- Interventions
- PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses, PRAX-222 - Fixed Doses, Placebo
- Drug · Procedure
- Lead sponsor
- Praxis Precision Medicines
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Developmental and Epileptic Encephalopathy
- Interventions
- LP352, Placebo
- Drug
- Lead sponsor
- Longboard Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 23 more
- Conditions
- SCN2A Encephalopathy, SCN8A Encephalopathy
- Interventions
- PRAX-562
- Drug
- Lead sponsor
- Praxis Precision Medicines
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Minneapolis, Minnesota + 1 more
- Conditions
- Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
- Interventions
- XEN496
- Drug
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Industry
- Eligibility
- 1 Month to 6 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Tacoma, Washington
- Conditions
- SCN8A Developmental and Epileptic Encephalopathy Syndrome
- Interventions
- NBI-921352
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 2 Years to 22 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more
- Conditions
- SCN2A-DEE, Epilepsy
- Interventions
- Not listed
- Lead sponsor
- Praxis Precision Medicines
- Industry
- Eligibility
- 1 Year to 16 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia